Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial - Merz, Maximilian; Mai, Elias K.; Bertsch, Uta; Hose, Dirk; Seckinger, Anja; Jauch, Anna; Hillengaß, Jens; Raab, Marc-Steffen; Schurich, Bärbel; Goldschmidt, Hartmut (Haematologica, 2015)
Gesehen am 13.04.2017